The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis
Speakers' Bureau - Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; QED Therapeutics
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Gary D. Steinberg
Stock and Other Ownership Interests - UroGen pharma
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; CG Oncology; Ferring; Janssen; Merck; Pfizer; Photocure; Seagen
 
Juergen Gschwend
No Relationships to Disclose
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Audrey Richiero
Employment - Bristol-Myers Squibb (Mexico)
 
Alexandre Lambert
Employment - Bristol-Myers Squibb
 
Bradley Raybold
Employment - Bristol-Myers Squibb
 
Srikanth Gajavelli
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Dimitrios Zardavas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792